HAYWARD, CA, November 7, 2000 - Sepragen Corporation (OTC BB:
SPGNA), a provider of patented technology and equipment for purification needs
in the nutritional and biotech industries, today has announced the addition of
Jim Spradling as acting President and COO. Jim has joined the company as a
consultant in the capacity of acting President and COO and will formally become
President and COO after completion of a proposed financing for the company.
Jim has a distinguished professional track record with over 32
years executive management experience at Raychem. Jim joined Raychem when
it was under $10 million in revenues and left as Senior Vice President when the
company had grown to over $1.6 billion. Jim had P & L responsibility
for a $400 million sector. During his tenure at Raychem, Jim directed the
corporate technical center and established and managed several international
operations and joint ventures. No stranger to technology and
entrepreneurial endeavors, Jim said, "I believe Sepragen has a tremendous
technology portfolio, a dedicated team and significant growing market
opportunities. I look forward to helping Sepragen transition to its
commercialization phase."
Welcoming Jim, Vinit Saxena, Sepragen's Chairman, commented,
"We are excited about Jim joining Sepragen. I believe that Jim can
contribute the management depth and experience needed to help transition our
vision into commercially vibrant opportunity. We are working on securing
additional capital to undertake this transition."
Sepragen Corporation is a leading supplier of separation process
technology, equipment and consumables to the biotechnology and nutraceutical
industries. In addition to its biotech drug separation business, the
company has developed patented applications that provide large market
opportunities in the food and beverage industry, including debittering citrus
juices, extracting isoflavone (plant estrogen) from soy, as well as extracting
proteins from whey. The company holds over 14 issued patents relating to
its core technology.
